What happened
DataMeds AI, Inc. (NASDAQ: MEDS) said on October 13, 2026, that it signed an intellectual property license and services deal with REBOOT Health AI, Inc. REBOOT granted DataMeds an exclusive U.S. license for GLP-1 user management in its direct-to-consumer weight management business. The license does not cover direct sales of REBOOT technology to healthcare providers, except for limited exceptions. DataMeds also said it cannot get source code or change the platform, and REBOOT keeps the platform and later upgrades.
In exchange, DataMeds must issue REBOOT 666,667 shares valued at $2 million and pay $50,000 within two business days. If the shares are worth less than $2 million after 180 days, DataMeds must issue more stock to make up the difference. The agreement runs until the last licensed patent expires or is invalid, unless an uncured material breach ends it earlier.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| Stockholders' equity | more than $2.5 million | from ($12.45 million), +$14.95 million minimum | SEC 8-K |
| Vendor payables converted to common stock | approximately $1.5 million | SEC 8-K | |
| Debt extinguished in settlement | approximately $18.7 million | SEC 8-K | |
| REBOOT common shares issued | 666,667 shares | SEC 8-K |
Why it matters
The filing says these transactions lifted stockholders' equity above Nasdaq's $2.5 million floor. DataMeds said it converted about $1.5 million of vendor payables into common stock from July 2026 to October 2026. It also said a settlement agreement and release extinguished about $18.7 million of debt. The related product and services agreement requires REBOOT to provide products and services for the reconfigured platform, and a revenue-sharing deal gives REBOOT part of adjusted gross revenue after certain costs.
Against the $(12,447,801) stockholders' deficit reported for the fiscal year ended December 31, 2025, OptimistFi's calculation shows at least $14.95 million of improvement. That supports the listing case, but Nasdaq has not confirmed compliance and says delisting proceedings could follow if the next periodic report does not show compliance.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
What's next
DataMeds said it is waiting for Nasdaq to formally confirm that it has shown compliance with the continued listing standard. Nasdaq will keep monitoring compliance, and the company's next periodic report is the next test of whether stockholders' equity stays above $2.5 million. A report that still shows compliance would support the listing case. A miss could trigger delisting proceedings.
More from OptimistFi
- MEDS stock: the DataMeds AI thesis, its status and the next test to watch
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- SEC 8-K — Current report dated October 13, 2026, filed October 16, 2026.
Read the full OptimistFi thesis on DataMeds AI, Inc.: https://optimistfi.com/stocks/MEDS
See what would break the DataMeds AI, Inc. thesis and track it live on the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
The full DataMeds AI, Inc. investment case, its status and the next test to watch live on the DataMeds AI, Inc. thesis page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
